TapImmune (NASDAQ:MRKR) had its target price cut by Piper Jaffray Companies from $10.00 to $6.00 in a research note issued to investors on Wednesday morning, The Fly reports. They currently have an overweight rating on the stock. Piper Jaffray Companies also issued estimates for TapImmune’s Q4 2019 earnings at ($0.14) EPS, FY2019 earnings at ($0.50) EPS, Q1 2020 earnings at ($0.14) EPS, Q2 2020 earnings at ($0.16) EPS, Q3 2020 earnings at ($0.17) EPS, Q4 2020 earnings at ($0.19) EPS, FY2020 earnings at ($0.66) EPS, Q1 2021 earnings at ($0.20) EPS, Q2 2021 earnings at ($0.22) EPS, Q3 2021 earnings at ($0.23) EPS and FY2021 earnings at ($0.91) EPS.
A number of other research analysts also recently issued reports on the company. ValuEngine upgraded TapImmune from a hold rating to a buy rating in a research note on Wednesday, October 2nd. Nomura reiterated a buy rating and set a $16.00 price objective on shares of TapImmune in a research note on Tuesday, August 13th. Janney Montgomery Scott reiterated a buy rating on shares of TapImmune in a research note on Sunday, July 21st. Finally, Zacks Investment Research downgraded TapImmune from a hold rating to a sell rating in a research note on Thursday, October 10th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. TapImmune presently has a consensus rating of Buy and an average price target of $10.15.
Shares of MRKR stock traded up $0.03 during mid-day trading on Wednesday, reaching $2.86. 375,700 shares of the company’s stock traded hands, compared to its average volume of 378,294. The company’s 50-day moving average price is $4.31 and its 200-day moving average price is $5.57. The company has a market cap of $129.40 million, a P/E ratio of -1.71 and a beta of 0.16. TapImmune has a 12 month low of $2.69 and a 12 month high of $9.17. The company has a quick ratio of 16.85, a current ratio of 15.83 and a debt-to-equity ratio of 0.01.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Further Reading: Guidelines for Successful Channel Trading
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.